Spain · Delayed Price · Currency is EUR Tubacex Earnings Call Transcripts
Fiscal Year 2025
-
Sales declined 6.3% to EUR 719.3 million, but profitability remained stable with a 14.17% EBITDA margin. The Abu Dhabi plant ramped up, supporting a robust order book and strong premium product mix, while the outlook for 2026 remains cautious amid ongoing uncertainty.
-
First half 2025 saw sales of EUR 361 million and EBITDA of EUR 61 million, with net profit up 140.9% year-over-year, driven by high-value contracts and the ADNOC license. Despite macroeconomic uncertainty and lower sales, margins and backlog remain strong, supporting a positive outlook.
Fiscal Year 2024
-
2024 saw major strategic advances, including a $200M Mubadala partnership, the launch of the Sentinel Prime connection, and strong multi-year contracts with ADNOC and Petrobras. EBITDA reached EUR 107M, with 2025 expected to be a record year as ADNOC billing begins.
-
Sales reached EUR 398 million with a 12.6% EBITDA margin, impacted by the ADNOC project ramp-up and high working capital. The Mubadala partnership and Abu Dhabi plant are set to drive strong sales and margin growth in 2025, with financial ratios expected to normalize post-cash inflow.